Rhythm Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Rhythm Pharmaceuticals, Inc.

Jan-09	Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones RYTM GlobeNewswire
Dec-11	Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome RYTM GlobeNewswire
Dec-10	Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome RYTM GlobeNewswire
Nov-10	Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek 2025 RYTM GlobeNewswire
Nov-07	Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE (setmelanotide) for Patients with Acquired Hypothalamic Obesity RYTM GlobeNewswire
Nov-05	Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program RYTM GlobeNewswire
Nov-04	Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update RYTM GlobeNewswire
Oct-21	Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 RYTM GlobeNewswire
Aug-27	Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences RYTM GlobeNewswire
Aug-20	Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity RYTM GlobeNewswire
Aug-05	Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update RYTM GlobeNewswire
Jul-22	Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 RYTM GlobeNewswire
Jul-12	Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025 RYTM GlobeNewswire
Jul-10	Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock RYTM GlobeNewswire
Jul-09	Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock RYTM GlobeNewswire
Jul-09	Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity RYTM GlobeNewswire
Jul-08	Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity RYTM GlobeNewswire
Jun-25	Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025 RYTM GlobeNewswire
May-14	Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program RYTM GlobeNewswire
May-07	Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update RYTM GlobeNewswire
May-06	Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences RYTM GlobeNewswire

Rhythm Pharmaceuticals, Inc.

Recent Articles by Rhythm Pharmaceuticals, Inc.

Upgrade your FINVIZ experience